Compare PNTG & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PNTG | CGEM |
|---|---|---|
| Founded | 2019 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 904.7M |
| IPO Year | 2019 | 2020 |
| Metric | PNTG | CGEM |
|---|---|---|
| Price | $34.10 | $16.35 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 8 |
| Target Price | ★ $37.00 | $30.13 |
| AVG Volume (30 Days) | 226.3K | ★ 956.5K |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 20.00 | N/A |
| EPS | ★ 0.24 | N/A |
| Revenue | ★ $947,705,000.00 | N/A |
| Revenue This Year | $24.72 | N/A |
| Revenue Next Year | $7.61 | $5.20 |
| P/E Ratio | $142.27 | ★ N/A |
| Revenue Growth | ★ 36.31 | N/A |
| 52 Week Low | $21.74 | $5.68 |
| 52 Week High | $37.54 | $16.74 |
| Indicator | PNTG | CGEM |
|---|---|---|
| Relative Strength Index (RSI) | 53.19 | 62.01 |
| Support Level | $28.05 | $11.92 |
| Resistance Level | $35.13 | N/A |
| Average True Range (ATR) | 1.59 | 1.03 |
| MACD | -0.22 | 0.08 |
| Stochastic Oscillator | 24.62 | 89.05 |
Pennant Group Inc is engaged in providing healthcare services to patients of all ages, including the growing senior population, in the United States. It operates in multiple lines of business including home health, hospice, and senior living which includes the company's assisted living, independent living, and memory care communities across Arizona, California, Colorado, Idaho, Montana, Nevada, Oklahoma, Oregon, Texas, Utah, Washington, Wisconsin, and Wyoming. It operates in two segments; home health and hospice services and senior living services. The company generates majority of its revenue from home health and hospice services segment, which includes its home health, hospice and home care businesses.
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.